Caliper Life Sciences Completes Previously Announced CRi Acquisition
Complete the form below to unlock access to ALL audio articles.
Caliper paid approximately $20 million in consideration for all of CRi's outstanding equity securities, which consisted of approximately $7.9 million in cash, approximately $1.8 million of assumed debt, and approximately 1.6 million shares of its common stock valued at approximately $10.3 million.
"We are excited to have completed this transaction which adds CRi's proprietary multiplexed in vivo and tissue imaging technology to Caliper's leading portfolio of drug discovery, imaging and diagnostics solutions," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "CRi's products provide an entry point for Caliper to address the expanding billion-dollar tissue imaging and digital pathology clinical research market. In addition, CRi's technologies enhance our toolkit of proprietary technologies for creating new product solutions to advance our vision to transform "sick care" to "health care" through next generation biomarker discovery, patient stratification studies and companion diagnostics for personalized medicine. We are pleased to welcome CRi to the Caliper team."
